2-Methyl-4-propan-2-yl-1,4-benzoxazin-3-one | 117278-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2-Methyl-4-propan-2-yl-1,4-benzoxazin-3-one
• CAS: 117278-85-0
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: SZTXWVATOUOIHT-UHFFFAOYSA-N

物化性质

• 沸点：
  373.9±31.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Methyl-4-propan-2-yl-1,4-benzoxazin-3-one 在 盐酸 、 三氯化铝 、 乙酸酐 、 肼 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 7.0h， 生成 2-methyl-6-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-4-propan-2-yl-1,4-benzoxazin-3-one
  参考文献：
  名称：

  6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents

  摘要：

  A series of 6-benzoxazinylpyridazin-3-ones was prepared and evaluated for inhibition of cardiac phosphodiesterase (PDE) fraction III in vitro and for positive inotropic activity in vivo. 6-[3,4-Dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl]-2,3,4,5-tetrahydro-5 - methylpyridazin-3-one (bemoradan) was found to be an extremely potent and selective inhibitor of canine PDE fraction III and a long-acting, potent, orally active inotropic vasodilator agent in various canine models. Additional benzoxazin-6-yl and -8-yl compounds were also prepared. Altering the pyridazinone substitution from the 6-position to the 7-position produced a 14-fold increase in the iv cardiotonic potency (ED50) from 77 to 5.4 micrograms/kg while substitution at the 8-position reduced potency. Methyl substitution at various sites in the molecule was also examined. Positive inotropic activity was maintained for between 8 and 24 h after a single oral dose (100 micrograms/kg) of bemoradan in dogs, thus making it one of the most potent and long-acting orally effective inotropes yet described. Bemoradan is currently under development as a cardiotonic agent for use in the management of congestive heart failure.

  DOI：

  10.1021/jm00163a061
• 作为产物：
  描述：

  2-氯丙酰氯 、 2-(丙烷-2-基氨基)苯酚 在 碳酸氢钠 作用下， 以 水 为溶剂， 反应 4.0h， 生成 2-Methyl-4-propan-2-yl-1,4-benzoxazin-3-one
  参考文献：
  名称：

  6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents

  摘要：

  A series of 6-benzoxazinylpyridazin-3-ones was prepared and evaluated for inhibition of cardiac phosphodiesterase (PDE) fraction III in vitro and for positive inotropic activity in vivo. 6-[3,4-Dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl]-2,3,4,5-tetrahydro-5 - methylpyridazin-3-one (bemoradan) was found to be an extremely potent and selective inhibitor of canine PDE fraction III and a long-acting, potent, orally active inotropic vasodilator agent in various canine models. Additional benzoxazin-6-yl and -8-yl compounds were also prepared. Altering the pyridazinone substitution from the 6-position to the 7-position produced a 14-fold increase in the iv cardiotonic potency (ED50) from 77 to 5.4 micrograms/kg while substitution at the 8-position reduced potency. Methyl substitution at various sites in the molecule was also examined. Positive inotropic activity was maintained for between 8 and 24 h after a single oral dose (100 micrograms/kg) of bemoradan in dogs, thus making it one of the most potent and long-acting orally effective inotropes yet described. Bemoradan is currently under development as a cardiotonic agent for use in the management of congestive heart failure.

  DOI：

  10.1021/jm00163a061

文献信息

• 6-Benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：EP0272914A2

  公开（公告）日：1988-06-29

  The synthesis of benzoxazinyl- and benzothiazinylpyridazinone compounds is described. The novel compounds are cardiotonic agents and inhibitors of phosphodiesterase. In addition, the compounds are useful as smooth muscle relaxants and bronchodilators.

  介绍了苯并恶嗪基和苯并噻嗪基哒嗪酮化合物的合成。 这些新型化合物是强心剂和磷酸二酯酶抑制剂。 此外，这些化合物还可用作平滑肌松弛剂和支气管扩张剂。
• (+) and (-) enantiomers of 5-aliphatic-6-(benzoxazinyl- or benzothiazinyl)-2,3,4,5-tetrahydropyridazin-3-ones
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：EP0509845A1

  公开（公告）日：1992-10-21

  The present invention relates to (+) and (-) enantiomers of compounds of the formula: as further defined herein. The compounds are useful as cardiotonic and vasodilating agents and as inhibitors of phosphodiesterase fraction III and platelet aggregation. In addition, the compounds are active as smooth muscle relaxants and bronchodilators.

  本发明涉及式中化合物的(+)和(-)对映体： 的对映体。这些化合物可用作强心剂和血管扩张剂，以及磷酸二酯酶 III 部分和血小板聚集的抑制剂。此外，这些化合物还具有平滑肌松弛剂和支气管扩张剂的活性。
• Antagonists of human integrin (α4)(β7)
  申请人：Morphic Therapeutic, Inc.

  公开号：US11174228B2

  公开（公告）日：2021-11-16

  Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

  所公开的是α4β7整合素的小分子拮抗剂，以及使用它们治疗一些特定疾病或病症的方法。
• Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity
  申请人：UCB BIOPHARMA SPRL

  公开号：US20160297837A1

  公开（公告）日：2016-10-13

  A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
• ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7)
  申请人：Morphic Therapeutic, Inc.

  公开号：US20200385352A1

  公开（公告）日：2020-12-10

  Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.